Quecitinib
Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases[1].
Product Specifications
CAS Number
2416858-84-7
Product Name Alternative
QY201
UNSPSC
12352005
Target
Cytochrome P450; JAK
Related Pathways
Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Smiles
O[C@H](C)C1=NC2=CN=C(NC=C3)C3=C2N1N4CCC(CC#N)CC4
Molecular Formula
C17H20N6O
Molecular Weight
324.38
References & Citations
[1]Wang JY, et al. The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. J Clin Pharmacol. 2025 May 27.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
JAK1; Tyk2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
